Biogen Inc. (NASDAQ:BIIB) on Wednesday agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion.
The company looks to further expand its immunology pipeline and broaden its reach into additional disease areas.
The deal includes an upfront payment to RayThera shareholders, with the majority of the consideration tied to future clinical and regulatory milestone achievements.
The transaction is expected to close in the third quarter of 2026.
Acquisition Adds Early-Stage Immunology Assets
